{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:25:14Z","timestamp":1793993114505,"version":"4.8.0"},"reference-count":58,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>To advance the use of circulating tumor DNA (ctDNA) applications, their broad clinical validity must be tested in different treatment settings, including targeted therapies. Using the prespecified longitudinal systematic collection of plasma samples in the phase 1\/2a LYM1002 trial (registered on www.clinicaltrials.gov as NCT02329847), we tested the clinical validity of ctDNA for baseline mutation profiling, residual tumor load quantification, and acquisition of resistance mutations in patients with lymphoma treated with ibrutinib+nivolumab. Inclusion criterion for this ancillary biological study was the availability of blood collected at baseline and cycle 3, day 1. Overall, 172 ctDNA samples from 67 patients were analyzed by the LyV4.0 ctDNA Cancer Personalized Profiling Deep Sequencing Assay. Among baseline variants in ctDNA, only TP53 mutations (detected in 25.4% of patients) were associated with shorter progression-free survival; clones harboring baseline TP53 mutations did not disappear during treatment. Molecular response, defined as a &amp;gt;2-log reduction in ctDNA levels after 2 cycles of therapy (28 days), was achieved in 28.6% of patients with relapsed diffuse large B-cell lymphoma who had \u22651 baseline variant and was associated with best response and improved progression-free survival. Clonal evolution occurred frequently during treatment, and 10.3% new mutations were identified after 2 treatment cycles in nonresponders. PLCG2 was the topmost among genes that acquired new mutations. No patients acquired the C481S BTK mutation implicated in resistance to ibrutinib in CLL. Collectively, our results provide the proof of concept that ctDNA is useful for noninvasive monitoring of lymphoma treated with targeted agents in the clinical trial setting.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004528","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T21:46:53Z","timestamp":1631224013000},"page":"4674-4685","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab"],"prefix":"10.1182","volume":"5","author":[{"given":"Alessio","family":"Bruscaggin","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodovico Terzi","family":"di Bergamo","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Spina","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Hodkinson","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Spring House, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Forestieri","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Bonfiglio","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adalgisa","family":"Condoluci","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland;"},{"name":"Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5277-9835","authenticated-orcid":false,"given":"Maria C.","family":"Pirosa","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8807-6146","authenticated-orcid":false,"given":"Martin R.","family":"Faderl","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Koch","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schaffer","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Spring House, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Spring House, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Fourneau","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Beerse, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5418-0949","authenticated-orcid":false,"given":"Bernhard","family":"Gerber","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Stussi","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5522-6109","authenticated-orcid":false,"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Balasubramanian","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Spring House, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland;"},{"name":"Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"},{"name":"Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"issue":"1","key":"2021111816212298600_B1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/hon.2704","article-title":"The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15-ICML workshop on ctDNA","volume":"38","author":"Rossi","year":"2020","journal-title":"Hematol Oncol."},{"issue":"1","key":"2021111816212298600_B2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med."},{"issue":"8","key":"2021111816212298600_B3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-018-0111-6","article-title":"Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort","volume":"8","author":"Bohers","year":"2018","journal-title":"Blood Cancer J."},{"issue":"12","key":"2021111816212298600_B4","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med."},{"issue":"28","key":"2021111816212298600_B5","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol."},{"issue":"5","key":"2021111816212298600_B6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol."},{"issue":"14","key":"2021111816212298600_B7","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood."},{"issue":"22","key":"2021111816212298600_B8","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood."},{"issue":"1","key":"2021111816212298600_B9","doi-asserted-by":"crossref","first-page":"14756","DOI":"10.1038\/ncomms14756","article-title":"Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia","volume":"8","author":"Yeh","year":"2017","journal-title":"Nat Commun."},{"issue":"12","key":"2021111816212298600_B10","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1158\/1078-0432.CCR-19-3418","article-title":"Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC","volume":"26","author":"Hellmann","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2021111816212298600_B11","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol."},{"key":"2021111816212298600_B12","author":"IMBRUVICA","year":"2019"},{"key":"2021111816212298600_B13","author":"IMBRUVICA","year":"2019"},{"issue":"5870","key":"2021111816212298600_B14","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science."},{"issue":"1","key":"2021111816212298600_B15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med."},{"issue":"24","key":"2021111816212298600_B16","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med."},{"issue":"18","key":"2021111816212298600_B17","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","article-title":"Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia","volume":"129","author":"Xu","year":"2017","journal-title":"Blood."},{"issue":"4","key":"2021111816212298600_B18","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/bloodadvances.2018029058","article-title":"Resistance mechanism for ibrutinib in marginal zone lymphoma","volume":"3","author":"Epperla","year":"2019","journal-title":"Blood Adv."},{"key":"2021111816212298600_B19","author":"OPDIVO","year":"2020"},{"key":"2021111816212298600_B20","author":"OPDIVO","year":"2020"},{"issue":"5","key":"2021111816212298600_B21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2021","journal-title":"Blood."},{"issue":"6","key":"2021111816212298600_B22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021111816212298600_B23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.15508","article-title":"Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre","volume":"185","author":"Rogers","year":"2019","journal-title":"Br J Haematol."},{"issue":"27","key":"2021111816212298600_B24","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"issue":"5","key":"2021111816212298600_B25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol."},{"key":"2021111816212298600_B26","author":"International Cancer Genome Consortium"},{"issue":"11","key":"2021111816212298600_B27","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.18632\/oncotarget.653","article-title":"Recurrent targets of aberrant somatic hypermutation in lymphoma","volume":"3","author":"Khodabakhshi","year":"2012","journal-title":"Oncotarget."},{"issue":"5","key":"2021111816212298600_B28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published correction appears in Nat Med. 2018;24(8):1292]","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med."},{"issue":"4","key":"2021111816212298600_B29","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell."},{"issue":"11","key":"2021111816212298600_B30","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J Exp Med."},{"issue":"12","key":"2021111816212298600_B31","doi-asserted-by":"crossref","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med."},{"issue":"6","key":"2021111816212298600_B32","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of \u03b22-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell."},{"issue":"4","key":"2021111816212298600_B33","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov."},{"issue":"10","key":"2021111816212298600_B34","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"2021111816212298600_B35","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2159-8290.CD-19-0116","article-title":"Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma","volume":"10","author":"Mondello","year":"2020","journal-title":"Cancer Discov."},{"issue":"7","key":"2021111816212298600_B36","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.celrep.2015.10.008","article-title":"Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression","volume":"13","author":"Mottok","year":"2015","journal-title":"Cell Rep."},{"issue":"10","key":"2021111816212298600_B37","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/annonc\/mdz227","article-title":"How liquid biopsies can change clinical practice in oncology","volume":"30","author":"Siravegna","year":"2019","journal-title":"Ann Oncol."},{"issue":"1","key":"2021111816212298600_B38","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3324\/haematol.2019.237719","article-title":"Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study","volume":"106","author":"Camus","year":"2021","journal-title":"Haematologica."},{"issue":"6","key":"2021111816212298600_B39","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica."},{"issue":"1","key":"2021111816212298600_B40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood-2018-07-865428","article-title":"Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016","volume":"133","author":"Qu","year":"2019","journal-title":"Blood."},{"issue":"19","key":"2021111816212298600_B41","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood."},{"issue":"7","key":"2021111816212298600_B42","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/ijc.30838","article-title":"TP53 mutation and survival in aggressive B cell lymphoma","volume":"141","author":"Zenz","year":"2017","journal-title":"Int J Cancer."},{"issue":"4","key":"2021111816212298600_B43","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol."},{"issue":"12","key":"2021111816212298600_B44","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol."},{"issue":"13","key":"2021111816212298600_B45","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N Engl J Med."},{"issue":"9","key":"2021111816212298600_B46","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med."},{"issue":"5","key":"2021111816212298600_B47","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med."},{"issue":"8","key":"2021111816212298600_B48","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamaoncol.2019.0512","article-title":"Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"issue":"3","key":"2021111816212298600_B49","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","article-title":"Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction","volume":"178","author":"Kurtz","year":"2019","journal-title":"Cell."},{"issue":"1","key":"2021111816212298600_B50","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2352-3026(20)30365-3","article-title":"The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma","volume":"8","author":"Barrington","year":"2021","journal-title":"Lancet Haematol."},{"issue":"1","key":"2021111816212298600_B51","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(20)30357-4","article-title":"The role of PET in first-line treatment of Hodgkin lymphoma","volume":"8","author":"Trotman","year":"2021","journal-title":"Lancet Haematol."},{"issue":"5","key":"2021111816212298600_B52","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/bjh.14857","article-title":"Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors","volume":"182","author":"Jain","year":"2018","journal-title":"Br J Haematol."},{"issue":"12","key":"2021111816212298600_B53","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood."},{"issue":"23","key":"2021111816212298600_B54","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol."},{"issue":"4","key":"2021111816212298600_B55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell."},{"issue":"5","key":"2021111816212298600_B56","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol."},{"issue":"1","key":"2021111816212298600_B57","doi-asserted-by":"crossref","first-page":"100977","DOI":"10.1016\/j.tranon.2020.100977","article-title":"Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter\u2019s transformation","volume":"14","author":"Hodkinson","year":"2021","journal-title":"Transl Oncol."},{"issue":"7","key":"2021111816212298600_B58","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41591-020-0915-3","article-title":"Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring","volume":"26","author":"Zviran","year":"2020","journal-title":"Nat Med."}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2022007909","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/22\/4674\/1835899\/advancesadv2021004528.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/22\/4674\/1835899\/advancesadv2021004528.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T17:21:25Z","timestamp":1637256085000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/22\/4674\/476850\/Circulating-tumor-DNA-for-comprehensive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":58,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2021,11,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004528","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2022007909","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]}}}